NASDAQ · OBIO
Healthcare · Biotechnology
$5.36
Down-$0.07 (-1.29%)
Updated Aug 22, 2026, 9:28 PM
SID Score
6.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
OBIO closed at $5.36 after 21 trading sessions, up 43.32% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $5.45 | $5.53 | $5.27 | $5.36 | 276.67K |
| Aug 20, 2026 | $5.53 | $5.58 | $5.38 | $5.43 | 209.56K |
| Aug 19, 2026 | $5.492 | $5.78 | $5.49 | $5.55 | 463.86K |
| Aug 18, 2026 | $4.74 | $5.77 | $4.69 | $5.66 | 2.06M |
| Aug 17, 2026 | $4.41 | $4.72 | $4.36 | $4.72 | 221.59K |
| Aug 14, 2026 | $4.47 | $4.47 | $4.29 | $4.41 | 142.77K |
| Aug 13, 2026 | $4.46 | $4.545 | $4.40 | $4.45 | 226.83K |
| Aug 12, 2026 | $4.39 | $4.47 | $4.20 | $4.42 | 207.75K |
| Aug 11, 2026 | $4.27 | $4.66 | $4.27 | $4.40 | 345.49K |
| Aug 10, 2026 | $4.25 | $4.495 | $4.25 | $4.46 | 166.41K |
| Aug 7, 2026 | $4.17 | $4.285 | $4.14 | $4.24 | 103.92K |
| Aug 6, 2026 | $4.21 | $4.26 | $4.03 | $4.15 | 149.13K |
| Aug 5, 2026 | $4.27 | $4.27 | $4.135 | $4.22 | 148.28K |
| Aug 4, 2026 | $4.10 | $4.29 | $4.10 | $4.27 | 151.8K |
| Aug 3, 2026 | $3.97 | $4.15 | $3.935 | $4.12 | 187.24K |
| Jul 31, 2026 | $3.98 | $4.0585 | $3.8428 | $3.98 | 153.85K |
| Jul 30, 2026 | $3.83 | $4.00 | $3.83 | $3.99 | 144.2K |
| Jul 29, 2026 | $3.85 | $3.95 | $3.78 | $3.80 | 256.02K |
| Jul 28, 2026 | $3.83 | $3.89 | $3.815 | $3.86 | 194.38K |
| Jul 27, 2026 | $3.80 | $3.88 | $3.75 | $3.82 | 180.78K |
| Jul 24, 2026 | $3.67 | $3.79 | $3.615 | $3.74 | 149.34K |
The latest Smart Investors Daily articles mentioning OBIO.
OBIO research
Company profile and research snapshot.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | Piper Sandler | Overweight | — |
| May 19, 2026 | B. Riley Securities | Buy | — |
| May 14, 2026 | HC Wainwright & Co. | Buy | — |
| May 13, 2026 | Barclays | Overweight | — |
| Mar 12, 2026 | Chardan Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 11, 2026
Piper Sandler analyst Matt O'Brien reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $9 to $10.
Yahoo · Aug 10, 2026
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of -8.57% and -32.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Benzinga · Aug 10, 2026
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.37) by 2.7 percent. This is a 24 percent increase over losses of $(0.50) per share
SeekingAlpha · Jul 22, 2026
Orchestra BioMed nears pivotal trial readouts for AVIM Therapy & Virtue SAB, backed by Medtronic/Terumo. Click to see catalysts, valuation & upside.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OBIO.
